Clinical efficacy of Huazhuojieduruanganfang combined with ursodeoxycholic acid in treating 60 cases with primary biliary cirrhosis

Abstract

Abstract: Objective To observe the effects on cholestasis indicators of Huazhuo Jiedu Ruangan decoction in patients with primary biliary cirrhosis. Methods 60 cases of patients with primary biliary cirrhosis were randomly divided into two groups, the patients of the control group oraled ursodeoxycholic acid (UDCA);the patients of the treatment group taken Huazhuo Jiedu Ruangan decoction beside UDCA. The effects on cholestasis indicators of Huazhuo Jiedu Ruangan decoction in patients with primary biliary cirrhosis, and the biochemical indicators of cholestasis before and after the treatment were observed. Results The results showed that biochemical indicators in the treatment group improved significantly better than that of the control group, the difference was significant (P<0.05). Conclusion Cholestasis indicators of the patients with primary biliary cirrhosis treated with Huazhuo detoxification decrease significantly.

Key words: Huazhuo Jiedu Ruangan decoction, integrative medicine, primary biliary cirrhosis, biochemical indicator

CLC Number:

R256.4

References

[1] 陈国庆, 杨素莲, 黄建林, 古洁若, 李天旺, 陆才生, 吴玉琼. 抗线粒体-M2抗体在原发性胆汁性肝硬化的意义 [J]. 现代检验医学杂志 2004.doi:10.3969/j.issn.1671-7414.2004.01.017
[2] 熊文生, 唐锡军, 王海燕, Xiong Wensheng, Tang Xijun, Wang Haiyan. 中西医结合治疗肝肾阴虚型肝硬化难治性腹水30例 [J]. 陕西中医 2006.doi:10.3969/j.issn.1000-7369.2006.01.004
[3] 李林, 钟德珍, 钟德雄. 中西医结合诊治胆汁性肝硬化32例临床观察 [J]. 北京中医 2002.doi:10.3969/j.issn.1674-1307.2002.05.014
[4] 蒋健, 何淼. 原发性胆汁性肝硬化的中医证候特点及疗效分析 [J]. 上海中医药大学学报 2003.doi:10.3969/j.issn.1008-861X.2003.03.005
[5] 吴其恺, 杨大国, 王植芳, 王松, 李慧涓. 中西医结合治疗病毒性黄疸型肝炎135例 [J]. 湖北中医杂志 2000.doi:10.3969/j.issn.1000-0704.2000.08.008
[6] 曾维政, 吴晓玲, 蒋明德, 陈晓斌, 秦建平, 邓桂英, ZENG Wei-zheng, Wu Xiao-Ling, JIANG Ming-De, CHEN Xiao-bin, QIN Jian-ping, DENG Gui-Ying. 复方红景天对肝纤维化大鼠肝组织Na+/Ca2+泵、TGF-β1 mRNA表达的影响 [J]. 第四军医大学学报 2005.doi:10.3321/j.issn:1000-2790.2005.17.006
[7] 叶任高, 陆再英. 内科学 [M]. 北京:人民卫生出版社 2006.
[8] Leuschner U. Primary biliary cirrhosis--presentation and diagnosis. [J]. Clinics in liver disease 2003, 4(4).
[9] Pares A, Rodes J. [J]. Clinics in liver disease 2003.
[10] HEATHCOTE E J. Management of primary biliary cirrhosis.The American Association for the study of liver diseases practice guidelines [J]. HEPATOLOGY 2000, 31(04).
[11] NGUYEN D L, JURAN B D, LAZARIDIS K N. Primary biliary cirrhos [J]. Best Pract Res Clin Gastroenterol 2010, 24(05).
[12] METCALF J V, MICHISON H C, PALME J M. Natural history of early primary cirrhosis [J]. LANCET 1996, 348(05).
[13] Ishibashi H, Shimoda S, Gershwin ME. [J]. Seminars in liver disease 2005.
[14] Ikuno N, Mackay IR, Jois J, Omagari K, Rowley MJ. Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis. [J]. Journal of gastroenterology and hepatology 2001, 12(12).
[15] 王宝恩, 张定凤. 现代肝脏病学 [M]. 北京:科学技术出版社 2003.
[16] Fukushima K, Ueno Y, Shimosegawa T. [J]. Hepatology research: the official journal of the Japan Society of Hepatology 2010.
[17] Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R, Clark V, Firpi RJ, Morelli G, Soldevila Pico C, Lindor K. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. [J]. Alimentary Pharmacology and Therapeutics 2011, 2(2).
[18] 尹有国. 病毒性肝炎的中医治疗 [M]. 北京:中国中医药出版社 1992.
[19] 洪照友, 高毅, 詹兴海. 中药虎杖对大鼠肝脏缺血性损伤保护的形态学观察 [J]. 世界华人消化杂志 1981, 8(01).